A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

NCT00499239 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped Unacceptable safety profile

Conditions

Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Multiple Myeloma

Interventions

DRUG: GS-9219

Sponsor

Gilead Sciences